ERBB2 and triple-negative breast carcinoma: In a prospective trial of 40 patients with HER2-positive and triple negative breast cancer, image-guided sampling of the breast with a median of 12 biopsies appeared to accurately diagnose pCR with a false negative rate of 5% [39].